Mizuho analyst Anthony Petrone raised the firm’s price target on Tandem Diabetes (TNDM) to $21 from $18 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion “under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes upgraded to Outperform from Neutral at Baird
- Citi ups Tandem target, adds ‘downside 90-day catalyst watch’
- Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley
- Tandem Diabetes Care Appoints Sandra Beaver to Board
- Tandem Diabetes price target raised to $17 from $13 at Morgan Stanley